CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04758650
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:27.828301+00:00
Published At: 2023-11-18T00:00:00+00:00
Record Updated At: 2023-11-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Malignancy Located in the Head and Neck", "Cancer", "Carotid Stenosis", "Atherosclerosis of Artery", "Hodgkin Lymphoma, Adult", "Non Hodgkin Lymphoma", "HLH", "Cardiac Sarcoidosis", "Sarcoidosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-18"
protocolSection.identificationModule.nctId: "NCT04758650"
protocolSection.identificationModule.officialTitle: "Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarco\u00efdosis"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.